USANA pre-announces Q3 net sales $265-$270M (down ~10% YoY); cuts FY2021 guidance

USANA HEALTH SCIENCES INC

Preliminary Q3 EPS $1.28-$1.33 vs $1.44 prior year; net sales $265-$270M vs $299M.
FY2021 guidance lowered: net sales $1.18-$1.20B (prev $1.24-$1.28B); EPS $5.80-$6.00 (prev $6.15-$6.50).
CEO cites COVID disruptions, lockdowns, postponed events, and delayed product launches as headwinds.
Board increases share repurchase authorization to $150M (includes $14M remaining).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.